A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients

BACKGROUND: The α/β ratio for prostate cancer is postulated being in the range of 0.8 to 2.2 Gy, giving rise to the hypothesis that there may be a therapeutic advantage to hypofractionation. To do so, we carried out a randomized trial comparing hypofractionated and conventionally fractionated image-...

Descripción completa

Detalles Bibliográficos
Autores principales: Norkus, Darius, Karklelyte, Agata, Engels, Benedikt, Versmessen, Harijati, Griskevicius, Romas, De Ridder, Mark, Storme, Guy, Aleknavicius, Eduardas, Janulionis, Ernestas, Valuckas, Konstantinas Povilas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846611/
https://www.ncbi.nlm.nih.gov/pubmed/24007322
http://dx.doi.org/10.1186/1748-717X-8-206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846611/
https://www.ncbi.nlm.nih.gov/pubmed/24007322
http://dx.doi.org/10.1186/1748-717X-8-206

Ejemplares similares